TY - JOUR
T1 - Models for angiogenesis
T2 - From fundamental mechanisms to anticancer treatment research
AU - Doumont, Gilles
AU - de Visser, Karin E.
AU - Derksen, Patrick W.B.
AU - Jonkers, Jos
N1 - Funding Information:
We apologize to those whose work was not included because of space considerations or whose papers were inadvertently omitted. Our work is supported by grants from EMBO (ALTF 502-2006 to G.D.), The Netherlands Organization for Scientific Research (VENI 916.056.135 to P.W.B.D.; VIDI 917.36.347 to J.J.) and the Dutch Cancer Society (NKI 2006-3486 to JJ.; NKI 2006-3715 to K.E.d.V. and J.J.).
PY - 2007
Y1 - 2007
N2 - Angiogenesis, the process of blood vessel formation, constitutes a critical step during embryonic development, cancer progression and metastasis formation. It also constitutes a key target for anticancer therapies. Over the past 20 years different in vitro, ex vivo and in vivo models have been used to understand the fundamental mechanisms of angiogenesis and to test new anti-angiogenic therapies. Here, we review the most important models and discuss their utility in basic and translational research.
AB - Angiogenesis, the process of blood vessel formation, constitutes a critical step during embryonic development, cancer progression and metastasis formation. It also constitutes a key target for anticancer therapies. Over the past 20 years different in vitro, ex vivo and in vivo models have been used to understand the fundamental mechanisms of angiogenesis and to test new anti-angiogenic therapies. Here, we review the most important models and discuss their utility in basic and translational research.
UR - https://www.scopus.com/pages/publications/40849135789
U2 - 10.1016/j.ddmod.2007.12.001
DO - 10.1016/j.ddmod.2007.12.001
M3 - Review article
AN - SCOPUS:40849135789
SN - 1740-6757
VL - 4
SP - 75
EP - 82
JO - Drug Discovery Today. Disease Models
JF - Drug Discovery Today. Disease Models
IS - 2
ER -